Get Your CAR T-Cell Therapy Manufacturing Under Control

Recent successes using CAR-T therapies have allowed investigators to expand their research fforts to a wide array of treatment possibilities for patients. Commercialization of autologous CAR T-cells brings about a host of challenges that biomanufacturers must solve in order to dvance their production pipelines. As such, implementation of process control and automa- ion, as well as assurance of supply, are key to consistent, high-quality CAR T-cell production. The use of functionally closed systems with the ability to monitor and control processes hrough online sensors can enable process control. Combined with the use of consistent, erum-free T-cell optimized media as well as low E&L, single-use consumables, this process can enable manufacturers to be well on their way to creating high-quality, potent therapies. In this GEN webinar, we will learn more about online monitoring for process control during he successful expansion of CAR T-cells.

A live Q&A session followed the presentation, offering you a chance to pose questions to our expert panelist.